MRA Applauds Expanded Approval of Pembrolizumab to Patients with Stage 2 Melanoma

The Melanoma Research Alliance (MRA) welcomes the US FDA decision to expand eligibility of Merck’s Keytruda to include patients with Stage IIB and IIC melanoma.